In this study we show that the endogenous cytokine TGF-β3 was produced specifically by developing T H 17 cells in an IL-23-dependent manner that was important for driving the pathogenic T H 17 phenotype. Whereas TGF-β1 plus IL-6 differentiated naive T cells into T H 17 cells, these T cells were not pathogenic unless they were further exposed to IL-23. We found that IL-23 was critical for enhancing the expression of and/or maintaining the endogenous amount of TGF-β3 in developing T H 17 cells. In fact, the differentiation of T H 17 cells in the presence of TGF-β3 and IL-6 made T H 17 cells pathogenic without any need for further exposure to IL-23. Through analysis of these subsets of pathogenic and nonpathogenic T H 17 cells, we have identified a molecular signature associated with pathogenic T H 17 cells.
RESULTS
Induction of TGF-b3 in T H 17 cells TGF-β1 and IL-6 are required for the differentiation of T H 17 cells 10, 12, 13 . However, T H 17 cells induced by TGF-β1 plus IL-6 are not pathogenic, unless they are further exposed to IL-23 for a prolonged period of time 21, 22 . In the EAE model, we adoptively transferred CD4 + T cells from mice of the 2D2 strain (which have transgenic expression of a T cell antigen receptor specific for myelin oligodendrocyte glycoprotein (MOG) amino acids ) and found that only the transfer of T cells differentiated with TGF-β1, IL-6 and IL-23 resulted in the induction of severe disease, whereas transfer of T cells differentiated with TGF-β1 and IL-6 resulted in the development of mild to no disease, with most recipient mice recovering rapidly within 20 d of the onset of clinical disease ( Fig. 1a and Table 1 ). To investigate the role of IL-23 in the induction of pathogenic T H 17 cells, we undertook detailed temporal microarray analysis that showed considerable induction of TGF-β3 in developing T H 17 cells exposed to TGF-β1, IL-6 and IL-23 ( Supplementary Fig. 1a) ; this was dependent on IL-23R signaling (Supplementary Fig. 1b) . Quantitative RT-PCR analysis confirmed the induction of TGF-β3 in T H 17 cells (Fig. 1b) . Naive T cells activated in the presence of TGF-β1 and IL-6 or in the presence of TGF-β1, IL-6 and IL-23 expressed TGF-β3. However, IL-23Rdeficient CD4 + T cells cultured under conditions of TGF-β1, IL-6 and IL-23 failed to enhance or maintain TGF-β3 expression ( Fig. 1c) . IL-23 was not required for the initial induction of TGF-β3, which was induced by IL-6 ( Supplementary Fig. 1c ), but the presence of IL-23R was required for the maintenance of TGF-β3 expression ( Fig. 1c) .
It remains unknown if cells of hematopoietic origin can produce TGF-β3. To investigate the expression of TGF-β3 protein, we generated TGF-β3-eYFP fate-reporter mice by crossing mice that express Cre recombinase in the locus encoding TGF-β3 (Tgfb3-Cre mice) 28 with reporter mice that express enhanced yellow fluorescent protein (eYFP) under control of the ubiquitous Rosa26 promoter. Analysis of lymphoid tissue from the offspring of that cross showed that TGF-β3 was produced in CD4 + T cells, CD8 + T cells, γδ T cells and B cells ( Fig. 1d) but not by cells of the myeloid lineage (CD11b + and/or Figure 1 The induction of TGF-β3 in T H 17 cells. (a) Clinical scores (indicative of disease incidence throughout) in wild-type recipients of naive 2D2 CD4 + T cells (5 × 10 6 ) differentiated in vitro with TGF-β1, IL-6 and IL-23 or with TGF-β1 and IL-6. (b) Quantitative RT-PCR analysis of Tgfb3 mRNA in naive CD4 + T cells differentiated for 4 d in vitro with TGF-β1, IL-6 and IL-23 (+) or no cytokines (−); results were calculated by the comparative threshold cycle method and are presented relative to those of Gapdh (internal control gene encoding glyceraldehyde phosphate dehydrogenase). (c) Quantitative RT-PCR analysis of Tgfb3 mRNA in naive wild-type (WT) or Il23r −/− CD4 + T cells differentiated in vitro with various combinations (below graph) of TGF-β1, IL-6 and IL-23 or no cytokines, presented as in b. (d) Expression of eYFP (TGF-β3) in CD4 + T cells, CD8 + T cells, γδ T cells and B cells from the lymph nodes and spleens of TGF-β3-eYFP fate-reporter mice, assessed by flow cytometry. Numbers in quadrants indicate percent cells in each throughout. (e) Expression of eYFP (TGF-β3) together with intracellular staining of IL-17 or IFN-γ in naive CD4 + T cells obtained from TGF-β3-eYFP fate-reporter mice (Tgfb3-Cre + ) and mice with Rosa26-driven eYFP expression without Tgfb3-Cre (Tgfb3-Cre − ), immunized with MOG(35-55) plus CFA; cells were cultured 4 d in vitro with IL-23 (MOG + IL-23) or without IL-23 (MOG) and then were stimulated with the phorbol ester PMA and ionomycin. (f) Intracellular staining of IL-17 and IFN-γ in splenocytes obtained from Tgfb3-Cre mice with Rosa26-driven expression of the diphtheria toxin receptor (DTR) and their littermates lacking Tgfb3-Cre (WT), both immunized with MOG(35-55) plus CFA and treated with diphtheria toxin 4 d later; cells were stimulated ex vivo with PMA and ionomycin. (g) IL-17 expression in naive CD4 + T cells from mice with loxP-flanked Tgfb3 alleles, cultured in vitro with IL-1β, IL-6 and IL-23 (T H 17) or no cytokines (T H 0), then transduced with control retroviral vector (Ctrl RV) or retroviral vector for Cre-GFP (Cre RV) for deletion of Tgfb3. NS, not significant; *P < 0.05 and **P < 0.01 (unpaired, two-tailed Student's t-test). Data are representative of more than three independent experiments with similar results (mean and s.d. in a-c). A small proportion of IL-17-expressing T cells and T cells that did not express IL-17 produced TGF-β3 after activation, but exposure to IL-23 largely restricted TGF-β3 expression to IL-17-producing T H 17 cells. This was true in both CD4 + T cell subsets ( Fig. 1e) and subsets without CD4 + T cells ( Supplementary Fig. 1c ). We also addressed whether TGF-β3 was also produced by IFN-γ-producing T H 1 cells, which are also induced by immunization with MOG(35-55) plus CFA. IFN-γ-producing T cells did not coexpress TGF-β3 ( Fig. 1e) . This was true for subsets without CD4 + T cells as well ( Supplementary Fig. 1d ), which suggested that TGF-β3 may have been expressed mainly by IL-17-producing cells. In addition, in the offspring of Tgfb3-Cre mice crossed with mice that express the diphtheria toxin receptor under control of the Rosa26 promoter that we immunized with MOG(35-55) plus CFA, deletion of TGF-β3 + cells in vivo through treatment of the mice with diphtheria toxin resulted in selective ablation of IL-17 + cells, whereas the number of IFN-γ + T cells remained unchanged ( Fig. 1f) . To further investigate the role of TGF-β3 in T H 17 differentiation, we isolated CD4 + T cells from mice with loxP-flanked Tgfb3 alleles in which Tgfb3 was deleted through the retroviral expression of a fusion of green fluorescent protein (GFP) and Cre recombinase and found that the deletion of TGF-β3 in CD4 + T cells severely compromised IL-17 production in T H 17 differentiation conditions, but T cells from such mice that were treated with control retrovirus did not demonstrate this effect ( Fig. 1g) . These findings showed that T H 17 cells produced TGF-β3 endogenously and that exposure to IL-23 largely restricted the expression of TGF-β3 to IL-17-producing cells.
TGF-b3-induced T H 17 cells are highly pathogenic
To determine whether TGF-β3 can induce T H 17 cells, we polarized naive CD4 + T cells into T H 17 cells through the use of TGF-β1 and IL-6 or through the use of TGF-β3 and IL-6 and compared the expression of IL-17 and other T H 17 cell-associated molecules. T H 17 cells induced by TGF-β3 and IL-6 had expression IL-17 similar to that of T H 17 cells induced by TGF-β1 and IL-6 ( Fig. 2a,b ). Similar to TGF-β1induced T H 17 cells, TGF-β3-induced T H 17 cells expressed Rorc, Il17a
and Il17f but not Ifng (Fig. 2c) . However, TGF-β3-induced T H 17 cells had significantly higher expression of Il23r and Il22 than did TGF-β1-induced T H 17 cells ( Fig. 2d) . We confirmed the higher expression of IL-23R protein in TGF-β3-induced T H 17 cells in reporter mice in which the intracellular domain of IL-23R is replaced with GFP (IL-23R-GFP mice) 16 ( Fig. 2e) .
Because IL-23 induces T H 17 cells to become pathogenic and IL-23 can enhance and maintain the expression of TGF-β3, we investigated the pathogenicity of T H 17 cells induced by TGF-β3 and IL-6. We generated T H 17 cells from naive 2D2 T cells with TGF-β1 and IL-6 or with TGF-β3 and IL-6 and transferred those cells into naive recipient mice, then monitored the development of EAE. In contrast to the transfer of T H 17 cells induced by TGF-β1 and IL-6, which resulted in very mild disease, the transfer of T H 17 cells induced by TGF-β3 and IL-6 resulted in EAE with a high disease incidence, severity and mortality ( Fig. 2f and Table 1 ). Histopathological quantification of lesions in the central nervous system (CNS) showed significantly more parenchymal and meningeal inflammatory lesions in the group that received cells induced by TGF-β3 and IL-6 than in the recipients of T H 17 cells induced by TGF-β1 and IL-6 ( Fig. 2g) , which suggested that TGF-β3-induced T H 17 cells were highly pathogenic.
We next addressed how TGF-β1 and TGF-β3 were able to induce such a difference in the pathogenicity of T H 17 cells, given that both have been suggested to signal through a common receptor subunit, TGF-βRII 29, 30 . Mice expressing a dominant negative form of TGF-βRII generate fewer T H 17 cells and are protected from EAE 31 . We assessed whether TGF-β3, like TGF-β1, requires TGF-βRII for the development of T H 17 cells. To address this, we crossed mice expressing the dominant negative form of TGF-βRII with mice that have sequence encoding GFP knocked into the gene encoding IL-17A, then differentiated CD4 + T cells from the resultant reporter mice with TGF-β1 and IL-6 or with TGF-β3 and IL-6. Neither TGF-β1 nor TGF-β3 was able to induce the differentiation of T H 17 cells from T cells of these mice ( Supplementary Fig. 2a ), which suggested that both TGF-β1 and TGF-β3 signal through TGF-βRII for T H 17 differentiation ( Fig. 2a-c) .
To assess the possibility that TGF-βRII transmits different downstream signals after ligation with TGF-β1 or TGF-β3, we did a comprehensive PCR array analysis of TGF-β signaling in T H 17 cells generated with either TGF-β1 or TGF-β3. This array allowed us to determine the expression of approximately 90 known signaling molecules downstream of TGF-βRII and showed that TGF-β1 and TGF-β3 induced 
EAE in wild-type recipient mice given transfer of CD4 + T cells (genotype, far left column) cultured in the presence of various combinations of IL-23, TGF-β, IL-1β and IL-6 or antibodies (second column), followed by induction of active EAE with MOG(35-55) in CFA plus pertussis toxin. Disease incidence and mortality are presented as mice affected/total mice (with percentage in parentheses). Clinical scores and day of onset (mean ± s.e.m.) were calculated only for mice that developed clinical signs of EAE (NA (not applicable) indicates mice that did not develop EAE). Isotype, isotype-matched control antibody. Data are representative of at least three experiments, except experiments with anti-TGF-β3 and isotype-matched control antibody, which were repeated twice. *Versus 2D2 cells cultured with TGF-β3 + IL-6. † Versus 2D2 cells cultured with TGF-β1 + IL-6. ‡ Versus 2D2 cells cultured in the same conditions. § Versus cells cultured with anti-TGF-β3. || Versus Tbx21 −/− 2D2 cells cultured with TGF-β1 + IL-6.
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A r t i c l e s different expression profiles of target genes downstream of TGF-βRII engagement ( Supplementary Fig. 2b ). In particular, T H 17 cells differentiated through the use of TGF-β3 and IL-6 induced higher expression of the signal transducers Smad1 and Smad5 and lower expression of Smad3 than did those induced with TGF-β1 and IL-6 ( Fig. 2h) . Consistent with the PCR array data, TGF-β3 induced less phosphorylation of Smad2 and Smad3 than did TGF-β1, whereas the phosphorylation of Smad 1 and Smad5 was greatly enhanced ( Fig. 2i and Supplementary Fig. 2c ). Together these data indicated that T H 17 cells induced by TGF-β3 and IL-6 were functionally distinct from T H 17 cells induced by TGF-β1 and IL-6 and that the difference in the functionality of T H 17 cells was supported by the differences in signaling induced by TGF-β1 and TGF-β3 through TGF-βRII.
TGF-b3-and IL-1b-, IL-6-and IL-23-induced T H 17 cells are similar TGF-β-independent T H 17 cells that are induced by a combination of IL-1β, IL-6 and IL-23 and are more pathogenic than those induced by TGF-β1 and IL-6 have been described 32 . We therefore induced pathogenic T H 17 cell populations by TGF-β3 and IL-6 or by IL-1β, IL-6 and IL-23 and compared their ability to transfer EAE. T H 17 cells differentiated under either condition had similar expression of IL-17 protein ( Fig. 3a) and Il23r mRNA (Fig. 3b) . Because the IL-23-IL-23R axis is essential for the development of pathogenic T H 17 cells [16] [17] [18] , we assessed whether the high expression of IL-23R contributed to the pathogenicity of T H 17 cells differentiated with TGF-β3 and IL-6 or with IL-1β, IL-6 and IL-23. We differentiated 2D2 T cells into T H 17 cells under those conditions and adoptively transferred those cells into wild-type recipients and found they transferred EAE with similar severity and incidence. Transfer of IL-23R-deficient 2D2 T cells failed to induce EAE under the differentiation conditions of TGF-β3 and IL-6 or of IL-1β, IL-6 and IL-23 ( Fig. 3c and Table 1 ). This indicated that IL-23-IL-23R pathway was absolutely critical for the development of pathogenic T H 17 cells induced by TGF-β3 and IL-6 or by IL-1β, IL-6 and IL-23. Further analysis of T cells that infiltrated the CNS showed that T H 17 cells induced by TGF-β3 and IL-6 maintained higher IL-17 expression (~25% higher) and produce less IFN-γ (~15% less) than did T H 17 cells induced with IL-1β, IL-6 and IL-23 (data not shown).
To address whether TGF-β3 was involved in the induction of EAE after active immunization, we immunized mice with MOG(35-55) plus CFA, which is known to induce EAE by generating MOG(35-55)specific T H 1 and T H 17 cells. Analysis of CD4 + T cells that infiltrated the CNS of mice immunized with MOG(35-55) plus CFA showed significantly higher expression of Tgfb3 in mice that developed the disease (score = 2-3) than in mice with no clinical signs of disease (score = 0), even though there was infiltration of CD4 + T cells into the CNS of all these mice ( Fig. 3d) . Local blockade of TGF-β through the addition of neutralizing antibody to TGF-β1, TGF-β2 and TGF-β3 in the immunizing emulsion has been shown to prevent the development of T H 17 cells and EAE 31 , which would suggest an in vivo role for TGF-β in the development of T H 17 cells and this disease. However, that study 31 did not show which TGF-β is required for the development T H 17 cells, as that antibody neutralizes all three forms of TGF-β. We therefore determined whether neutralizing TGF-β3 locally affected the development of EAE. The inclusion of antibody to TGF-β3 (anti-TGF-β3) in the emulsion of MOG and CFA at the time of induction significantly inhibited the development of EAE ( Fig. 3e and Table 1 ), which suggested that endogenous TGF-β3 contributed to the induction of EAE. Together these data indicated that the pathogenic T H 17 cells induced by TGF-β3 had a pathogenic and functional phenotype similar to that of T H 17 cells induced by IL-1β, IL-6 and IL-23.
The transcriptional signature of pathogenic T H 17 cells
To characterize the molecular state associated with the functional differences between TGF-β1-and TGF-β3-induced T H 17 cells, we assessed the mRNA profiles of in vitro-differentiated T H 17 cells by whole-genome microarray. We compared the gene-expression profiles of naive CD4 + T cells differentiated into T H 17 cells under the following six polarizing conditions: IL-β1 and IL-6; IL-β1, IL-6 and IL-23; TGF-β1 and IL-6; TGF-β1, IL-6 and IL-23; TGF-β3 and IL-6; and TGF-β3, IL-6 and IL-23. As a control, we used activated T H 0 cells for baseline gene induction. We found 434 genes with a difference in expression that were upregulated or downregulated at least twofold in T H 17 cells relative to their expression in the control T H 0 cells (Fig. 4a) . For those 434 genes, the transcriptional profile of T H 17 cells differentiated with IL-1β andIL-6 or with IL-1β, IL-6 and IL-23 was similar to that of T H 17 cells differentiated with TGF-β3 and IL-6 or with TGF-β3, IL-6 and IL-23, whereas T H 17 cells differentiated with TGF-β1 and IL-6 or with TGF-β1, IL-6 and IL-23 had a distinct transcriptional profile (Fig. 4a) . Direct comparison of the transcriptional profiles of T H 17 cells differentiated with TGF-β1 and IL-6 or with TGF-β3 and IL-6 (chosen because these differentiation conditions led to substantial differences in the pathogenicity of T H 17 cells) identified 233 genes with differences in expression ( Supplementary Table 1 ).
On the basis of the biological function of their products, we selected a representative subset of 23 genes (Fig. 4b) and confirmed their differences in expression by quantitative PCR (Fig. 4c) .
The upregulated genes (Fig. 4b, left) represented the 'pathogenic signature' of TGF-β3-induced T H 17 cells, and the downregulated genes (Fig. 4b, right) represented the 'nonpathogenic signature' of TGF-β1-induced T H 17 cells. T H 17 cells induced by TGF-β3 and IL-6 were characterized by higher expression of transcripts that could be broadly divided into three different modules: those encoding cytokines and chemokines (Cxcl3, Ccl4, Ccl5, Ccl3, Csf2, Il3, Il22 and Casp1 (which encodes a molecule involved in the generation of mature IL-1β)); those encoding transcription factors (Tbx21 and Stat4); and those encoding effector molecules (Gzmb, Lag3 and Lglas3 (which encodes galectin-3)). In addition, T H 17 cells induced by TGF-β3 and IL-6 had downregulated expression of genes encoding molecules broadly associated with immunoregulation (regulatory module), including Il10, and genes encoding molecules involved in the regulation of IL-10 production (Ahr and Maf), as well as Il9, Il1rn and Ikzf3 (which encodes the transcription factor Aiolos), whereas T H 17 cells induced by TGF-β1 and IL-6 had upregulated expression of those genes (Fig. 4c) .
On the basis of the molecular signature reported above, we analyzed the profiles of each T H 17 population (Fig. 4d) . Principal-component analysis (PCA) identified three groups (I-III). Group I included T H 17 cells induced by TGF-β1 and IL-6 regardless of whether they were exposed to IL-23 or not; these cells had a mild or no pathogenic phenotype in vivo (Fig. 1a) and expressed little or no IL-23R (Fig. 2d,e ). Group II included T H 17 cells induced with TGF-β3 and IL-6 or with IL-1β and IL-6; these cells were highly pathogenic in vivo (Fig. 2f) and had high expression of IL-23R (Fig. 2d,e ). Group III included T H 17 cells induced with TGF-β3, IL-6 and IL-23 or with IL-1β, IL-6 and IL-23; these also had high expression of IL-23R (Fig. 3b) . Fig. 1b ). (c) Clinical scores of wild-type recipients (n, Table 1 ) after transfer of naive 2D2 or 2D2 Il23r −/− CD4 + T cells (5 × 10 6 ) differentiated in vitro with IL-1β, IL-6 and IL-23 or with TGF-β3 and IL-6. Right, linear-regression curve (as in Fig. 2f ). (d) Quantitative RT-PCR analysis of Tgfb3 mRNA in CNS-infiltrating CD4 + T cells isolated from wild-type mice immunized with MOG(35-55) in CFA plus pertussis toxin, with a score of 2-3 (peak of disease (EAE +)) or a score of 0 (no disease (EAE −); presented as in Fig. 1b) . (e) Clinical scores of wild-type mice (n, Table 1 ) immunized as in d, but with isotype-matched control antibody (WT) or neutralizing antibody to TGF-β3 (WT + anti-TGF-β3) in the emulsion. Right, linear-regression curve as in c. *P < 0.01 and **P < 0.001 (unpaired, two-tailed Student's t-test). Data are representative of at least three independent experiments (a,b) or are pooled from three independent experiments (c), three independent experiments with a total of 12 mice (d) or two independent experiments (e; mean and s.d. in b-e).
A r t i c l e s genes with different expression in T H 17 cells induced by TGF-β1 and IL-6 and those induced by TGF-β3 and IL-6 ( Fig. 4e) . These results showed that T H 17 cells induced by TGF-β3 and IL-6 were closely related to T H 17 cells induced by IL-1β and IL-6 and that they differed from T H 17 cells induced by TGF-β1 and IL-6. The 23-gene transcriptional signature of T H 17 cells defined here should provide a means of identifying key molecules involved in pathogenicity of T H 17 cells.
TGF-b3 overcomes the T-bet requirement for pathogenic T H 17 cells
Our microarray analysis showed that T H 17 cells induced by TGF-β3 and IL-6 had higher expression of Tbx21 (which encodes the transcription factor T-bet; Fig. 4b ). Because exposure of T H 17 cells to IL-23 induces the expression of T-bet 33 , we generated T H 17 cells from 2D2 T cells and Tbx21 −/− 2D2 T cells with TGF-β1, IL-6 and IL-23. Tbx21 −/− T H 17 cells had higher expression of IL-17A than did 2D2 T H 17 cells (Fig. 5a) ; however, transfer of Tbx21 −/− 2D2 T H 17 cells did not result in EAE, whereas transfer of 2D2 T H 17 cells induced disease with high incidence and severity (Fig. 5b) . These data indicated that T-bet had a key role in inducing the pathogenic functions of T H 17 cells and that this was independent of IL-17 production. Because TGF-β3 is required for the induction of pathogenic signatures in T H 17 cells, we assessed whether the inability of T-bet-deficient T cells to induce disease was due to lower TGF-β3 expression. In fact, TGF-β3 expression was lower in Tbx21 −/− cells than in wild-type cells (Fig. 5c) . Conversely, retroviral overexpression of T-bet enhanced the expression of TGF-β3 ( Fig. 5d) . We next assessed whether compensating for TGF-β3 in T-bet-deficient T H 17 cells would induce EAE in an adoptive-transfer system. Polarization of Tbx21 −/− 2D2 CD4 + T cells in the presence of TGF-β3 and IL-6 overcame the requirement for T-bet and the resultant cells were encephalitogenic, but polarization with TGF-β1, IL-6 and IL-23 or with TGF-β1 and IL-6 did not have this effect ( Fig. 5e and Table 1 ). Histological analysis showed that adoptively transferred Tbx21 −/− 2D2 cells induced by TGF-β3 and IL-6 produced CNS lesions in the meninges and the parenchyma, whereas Tbx21 −/− 2D2 cells induced by TGF-β1 and IL-6 produced no detectable lesions after transfer (Fig. 5f) . Tbx21 −/− T cells produced more IL-17 when differentiated with TGF-β1, IL-6 and IL-23 or with TGF-β3 and IL-6 than did wild-type T cells (Fig. 5g) . Published reports have suggested the requirement that IFN-γ-producing cells breach the blood-brain barrier to allow the entry of IL-17-producing cells into the CNS 34 . Analysis of CD4 + T cells isolated from the periphery or the CNS at the peak of disease showed that 2D2 cells induced by TGF-β3 and IL-6 expressed IFN-γ, but 2D2 Tbx21 −/− cells induced by TGF-β3 and IL-6 did not (Supplementary Fig. 3 ). This suggested that independently of IFN-γ production, Tbx21 −/− 2D2 T H 17 cells induced by TGF-β3 and IL-6 were pathogenic in vivo (Supplementary Fig. 3) . 
DISCUSSION
Although T H 17 cells have been associated with the induction of autoimmunity, emerging data suggest that not all T H 17 cell are pathogenic and that exposure to IL-23 is crucial for their ability to induce autoimmunity [16] [17] [18] 22 . In this paper we have shown that TGF-β3 endogenously produced by developing T H 17 cells had a critical role in inducing pathogenic T H 17 cells. We also found that T-bet, a transcription factor normally associated with T H 1 development, was critical for the generation of pathogenic T H 17 cells. Whereas mice deficient in IFN-γ or its receptor are highly susceptible to the development of EAE 7, 8 , mice that lack T-bet are protected from almost all autoimmune disease 9, 24 . Our data have begun to address this paradox by showing that T-bet was part of the pathogenic expression signature of a subset of T H 17 cells. Although it remains unclear how T-bet conferred encephalitogenic potential on T H 17 cells, we have shown that in the absence of T-bet, T H 17 cells were not able to induce endogenous TGF-β3. Whether T-bet directly transactivated TGF-β3 or indirectly modulated other receptors and/or factors in T H 17 cells is not clear at this stage. IL-23 signaling induces T-bet expression in T H 17 cells, and T-bet is suggested to induce IL-23R expression 35 , which suggests a feed-forward loop between IL-23R signaling and T-bet expression. Because of the T-bet expression in T H 17 cells, it has been postulated that T H 17 cells might produce IFN-γ and, therefore, that cells producing both IL-17 and IFN-γ are the main pathogenic T cells that induce autoimmune disease. Our data have suggested that the requirement for T-bet expression in pathogenic T H 17 cells is independent of IFN-γ production, because IFN-γ-deficient T H 17 cells induced with TGF-β3 and IL-6 were still able to induce EAE (data not shown). One possible reason for our finding of T-bet expression in T H 17 cells induced by TGF-β3 and IL-6 is that, unlike TGF-β1, which suppresses T-bet 36 and IL-23R 37 , TGF-β3 promotes the expression of these molecules, which would promote the stability and pathogenicity of T H 17 cells.
In addition to T-bet, several other factors were associated with the pathogenic expression signature of T H 17, including GM-CSF, IL-23R and IL-7R. GM-CSF, which is transactivated by RORγt, has been described as the key cytokine involved in the pathogenicity T H 17 cells 25, 26 , and our transcriptional analysis independently identified GM-CSF as a component of pathogenic T H 17 cells. Indeed, GM-CSFdeficient mice are highly resistant to EAE, and GM-CSF-deficient T H 17 cells are unable to transfer EAE 25, 26 . That is consistent with our data showing that pathogenic T H 17 cells induced by TGF-β3 and IL-6 expressed GM-CSF. However, it remains to be determined whether those T H 17 cells require GM-CSF for encephalitogencity. Similarly, IL-23R is a key component of the pathogenic T H 17 signature. IL-23R-deficient mice are resistant to EAE, and IL-23R-deficient T H 17 cells are unable to transfer EAE 16 . The IL-7-IL-7R pathway has also been linked to the development of T H 17 cells, and genetic data link IL-7R to susceptibility to multiple sclerosis in human patients 16, [38] [39] [40] [41] . However, the role of the IL-7-IL-7R axis in the induction of the pathogenic potential of T H 17 cells induced by TGF-β3 and IL-6 remains to A r t i c l e s be determined. Whether IL-7 simply expands pathogenic T H 17 cell populations or induces key molecules required for the pathogenicity of T H 17 cells has not been addressed yet. Systematic analysis of each of the molecules that belong to the pathogenic signature of T H 17 cells will allow the identification of key 'nodes' in the development of pathogenic T H 17 cells. Acquisition of a pathogenic phenotype by T H 17 cells is the consequence of not only the upregulation of genes encoding molecules that mediate pathology but also the downregulation of many other genes. We found that genes encoding molecules generally associated with immunoregulation, such as IL-10, Ahr and c-Maf, were significantly downregulated in pathogenic T H 17 cells. Ahr and c-Maf are induced by conditions of TGF-β1 and IL-6 (refs. [42] [43] [44] , and they work together to transactivate IL-10 production 45 . The failure of T H 17 cells induced by TGF-β3 and IL-6 to express these genes in might explain why these cells become highly pathogenic. Conversely, it should be determined whether T H 17 cells induced by TGF-β1 and IL-6 in the absence of the expression of Ahr, c-Maf or IL-10 can attain pathogenic functions. IL-10 has been associated with nonpathogenic T H 17 cells, and exposure to IL-23 has been shown to downregulate IL-10 production in T H 17 cells and enhance their encephalitogenicity 21, 22 . In addition to producing IL-10, nonpathogenic T H 17 cells produced the IL-1R antagonist IL-1RN, as well as soluble IL-6R, both of which would presumably inhibit signaling via IL-1 and IL-6 and thus further suppress the differentiation of pathogenic T H 17 cells. However, the relationship between IL-1R antagonism and IL-10 production by T H 17 cells remains unclear at this point. It remains to be determined whether different subsets of T H 17 cells (some that produce IL-17 and IL-10 and others that produce IL-17 and GM-CSF and express T-bet) have evolved to clear different types of pathogens. Indeed, observations of human T H 17 cells suggest that IL-17 + IL-10 + T H 17 cells are specific for infection with Staphylococcus aureus, whereas IL-17 + IFN-γ + T H 17 cells are specific for infection with Candida albicans 46 . Similarly, our study has suggested there are pathogenic and nonpathogenic subtypes of T H 17 cells and that their development may be contingent on the type of TGF-β present during the initial differentiation stage.
Existing data suggest that both pathogenic and nonpathogenic T H 17 cells exist in the repertoire. Although the initial differentiation of IL-17-producing cells is not dependent on exposure to IL-23, it is now clear that IL-23 is required for T H 17 cells to attain full pathogenic potential through its maintenance and stabilization of the T H 17 phenotype, suppression of IL-10 production, promotion of GM-CSF production and other effector molecules, and maintenance of TGF-β3 expression. The fact that the enhancement and maintenance of TGF-β3 are dependent on exposure to IL-23 is especially notable given that T H 17 cells differentiated with TGF-β1 and IL-6 did not transfer disease, yet when exposed to IL-23, they acquired pathogenic potential and induced autoimmune disease. Thus, it is likely that the IL-23-dependent production of TGF-β3 in T H 17 cells differentiated with TGF-β1 and IL-6 is required for induction of the full pathogenic phenotype in T H 17 cells for the induction of autoimmunity.
In summary, we have reported here a critical role for TGF-β3 autonomously produced by T H 17 cells in the induction of pathogenic T H 17 cells. Whereas both TGF-β1 and TGF-β3 were able to induce T H 17 cells, T H 17 cells induced by TGF-β3 and those induced by TGF-β1 differed in many ways. T H 17 cells induced by TGF-β3 were not only pathogenic in inducing EAE but also very potent in inducing colitis in the adoptive-transfer model (data not shown), which supports the proposal of a broader role for TGF-β3 in inducing very pathogenic and proinflammatory T H 17 cells. As TGF-β3 induces pathogenic T H 17 cells in both EAE and colitis, TGF-β3 may prove a useful target for the regulation of tissue inflammation in many autoimmune diseases.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE39820.
Note: Supplementary information is available in the online version of the paper.
